Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Core Points - The company held its second extraordinary general meeting of shareholders in 2025 on July 31, 2025, with a total of 978 shareholders present, representing 3,210,215,774 shares, which is 48.8419% of the total voting shares [3][4] - The meeting approved the appointment of the accounting firm for the 2025 fiscal year with 99.1053% of the votes in favor, and a special resolution to amend the company's articles of association with 90.2621% approval [7][8] Meeting Details - The meeting was held at the Nanjiao Hotel in Shanghai and combined on-site and online voting methods [3] - The meeting was convened by the sixth board of directors and presided over by the vice chairman and general manager, Jun Xu [3] Attendance - A total of 973 minority shareholders participated, representing 798,538,266 shares, which is 12.1494% of the total voting shares [6] - The total share capital of the company as of the registration date was 6,637,984,837 shares, with 65,321,952 shares held in the repurchase account excluded from voting rights [6] Voting Results - The proposal to appoint the accounting firm received 3,181,494,720 votes in favor, with only 27,235,854 votes against [7] - The special resolution to amend the articles of association received 2,897,608,048 votes in favor, with 311,532,426 votes against [8] Legal Opinion - The legal opinion provided by King & Wood Mallesons confirmed that the meeting's procedures complied with relevant laws and regulations, and the voting results were valid [10]

北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》 （以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民 共和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特 别行政区、中国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、 规章、规范性文件和现行有效的《上海莱士血液制品股份有限公司章程》 （以下 简称《公司章程》）的有关规定，指派律师出席了公司于 2025 年 7 月 31 日召 开的 2025 年第二次临时股东大会（以下简称本次股东大会），并就本次股东大 会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限 于： 海莱士血液制品股份有限公司第六届董事会第十二次（临时）会议决议 的公告》； 公司已向本所保证，公司已向本所提供了 ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，上海莱士发布公告称，公司2025年第二次临时股东大会于2025年7月31日 召开，审议通过了《关于聘任2025年度会计师事务所的议案》等。 ...

证券代码：002252 证券简称：上海莱士 公告编号：2025-055 上海莱士血液制品股份有限公司 2025 年第二次临时股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在增加、变更、否决提案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议； 3、本次会议提案涉及股东大会特别决议事项，按照《公司章程》规定，本次特 别决议事项需经出席会议股东（包括股东代理人）所持表决权 3/4 以上表决同意后方 可通过。 一、会议召开和出席情况 （一）会议召开情况 1、现场会议召开时间为：2025 年 7 月 31 日（星期四）14:00； 网络投票时间为：2025 年 7 月 31 日（星期四）； 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 7 月 31 日的交易时间，即 9:15－9:25，9:30－11:30，13:00－15:00；通过深圳证券交易所 互联网投票系统投票的具体时间为：2025 年 7 月 31 日 9:15 至 15:00 期间的任意时 间； 2、现场会议召开 ...

1. 经公司 2024 年第三次临时股东大会审议通过的《公司章程》； 2. 公司 2025 年 7 月 16 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届董事会第十二次（临时）会议决议 的公告》； 3. 公司 2025 年 7 月 16 日刊登于巨潮资讯网及深圳证券交易所网站的《上 海莱士血液制品股份有限公司第六届监事会第七次会议决议的公告》； 公司已向本所保证，公司已向本所提供了本所为出具本法律意见书所要求 公司提供的原始书面材料、副本材料、复印材料、承诺函或证明，并无隐瞒记 载、虚假陈述和重大遗漏之处；公司提供给本所的文件和材料是真实、准确、 完整和有效的，且文件材料为副本或复印件的，其与原件一致和相符。 北京市金杜（青岛）律师事务所 关于上海莱士血液制品股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：上海莱士血液制品股份有限公司 北京市金杜（青岛）律师事务所（以下简称本所）接受上海莱士血液制品 股份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简 称《证券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监 督管理委员会《 ...

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector is as follows: - Below 500,000 yuan: 153 individuals (32%) - 500,000 to 1 million yuan: 199 individuals (41%) - 1 million to 2 million yuan: 114 individuals (23%) - 2 million to 3 million yuan: 16 individuals (3%) - Over 3 million yuan: 5 individuals (1%) [5] Age Distribution - The age distribution of company secretaries shows that: - Ages 40-50: 47% - Ages 50 and above: 23% - Ages 30-40: 29% - Under 30: 1%, with the youngest being 28 years old [1] Educational Background - The educational qualifications of company secretaries are as follows: - Associate degree: 4% - Bachelor's degree: 42% - Master's degree: 50% - Doctorate: 4% - More than half of the company secretaries hold a master's degree or higher [3] Investor Engagement - The frequency of investor engagements varies significantly among companies: - Less than 10 times: 129 companies (32%) - 10 to 100 times: 149 companies (37%) - 100 to 300 times: 79 companies (20%) - 300 to 1000 times: 42 companies (10%) - More than 1000 times: 5 companies (1%) [7] Top Investor Engagement Companies - The companies with the highest number of investor engagements are: - Sanofi Biologics: 2,661 times - Bohui Innovation: 1,500 times - Zexin Pharmaceutical: 1,418 times - Aibo Medical: 1,263 times - Kangtai Medical: 1,107 times [9]

金融界消息 截至2025年7月30日收盘，上海莱士（002252）报收于6.99元，下跌0.43%，换手率0.96%， 成交量63.45万手，成交金额4.45亿元。 天眼查商业履历信息显示，上海莱士血液制品股份有限公司，成立于1988年，位于上海市，是一家以从 事医药制造业为主的企业。企业注册资本663798.4837万人民币，实缴资本663798.4837万人民币。公司 法定代表人为Jun Xu。 通过天眼查大数据分析，上海莱士血液制品股份有限公司共对外投资了25家企业，参与招投标项目690 次，知识产权方面有商标信息40条，专利信息38条，此外企业还拥有行政许可360个。 来源：金融界 资金流向方面，今日主力资金净流出3894.84万元，占比成交额8.75%。其中，超大单净流出1717.01万 元、占成交额3.86%，大单净流出2177.83万元、占成交额4.89%，中单净流出流入690.60万元、占成交 额1.55%，小单净流入3204.24万元、占成交额7.2%。 上海莱士最新一期业绩显示，截至2025一季报，公司营业总收入20.06亿元、同比减少2.45%，归属净利 润5.66亿元，同比减少25.2 ...

Group 1 - The medical health ETF Taikang (159760) has seen a 1.36% increase, marking its seventh consecutive rise, with a trading volume of 6.12% and a transaction value of 5.4675 million yuan, closing at 0.67 yuan [1] - The National Index for Public Health and Medical Health (980016) has risen by 1.42%, with significant gains in constituent stocks such as Teva Biopharmaceuticals (688278) up 10.99%, China Resources Double Crane (600062) up 7.97%, and Kelun Pharmaceutical (002422) up 5.93% [1] - Over the past week, the medical health ETF Taikang has accumulated a 6.08% increase, with its latest scale reaching 88.3645 million yuan, a three-month high [1] Group 2 - The National Healthcare Security Administration (NHSA) has initiated the 11th batch of centralized procurement, emphasizing principles of "stabilizing clinical practices, ensuring quality, preventing collusion, and countering internal competition" [2] - The NHSA has optimized procurement rules, moving away from a simple lowest price reference, which is expected to gradually improve drug prices in the pharmaceutical industry [2] - The NHSA's measures are anticipated to enhance the profitability of pharmaceutical companies as drug price competition returns to a healthier state [2] Group 3 - As of June 30, 2025, the top ten weighted stocks in the National Index for Public Health and Medical Health (980016) include WuXi AppTec (603259), Hengrui Medicine (600276), Mindray Medical (300760), and others, collectively accounting for 51.67% of the index [3]

Investment Rating - The report maintains a "Buy" rating for the company [6][13]. Core Viewpoints - The company is experiencing rapid growth in plasma collection, with new production capacity expected to enhance production efficiency and new product approvals likely to improve the comprehensive utilization rate of plasma [2][13]. - The company has a strong advantage in acquiring plasma station resources, supported by its affiliation with the China National Pharmaceutical Group [21][22]. - The company is expected to achieve significant revenue growth, with projected revenues of 72.98 billion, 86.42 billion, and 99.26 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 21.0%, 18.4%, and 14.9% [15][19]. Financial Summary - Total revenue is projected to grow from 51.80 billion yuan in 2023 to 99.26 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 14.9% [4][15]. - Net profit attributable to the parent company is expected to increase from 11.10 billion yuan in 2023 to 22.40 billion yuan in 2027, with a CAGR of approximately 15.4% [4][15]. - Earnings per share (EPS) is forecasted to rise from 0.56 yuan in 2023 to 1.13 yuan in 2027 [4][15]. Industry Insights - The blood product industry is expected to see a rise in demand, particularly for domestic alternatives to imported human albumin, with a significant portion of the market still untapped for immunoglobulin and coagulation factor products [18][19]. - The industry is witnessing an increase in plasma collection capacity, with a projected 11% growth in plasma collection volume in 2024 [19][23]. - The concentration of plasma stations among leading companies is increasing, with the top companies holding a significant share of the market [20][23]. Production Capacity and Efficiency - The company has planned three new production facilities, each with a capacity of 1,200 tons per year, which will enhance overall production capacity to over 4,000 tons annually [29][31]. - The integration of production facilities has led to improved operational efficiency and increased yield rates for key products [27][29]. Research and Development - The company is focusing on enhancing its R&D capabilities, with a diverse pipeline of products aimed at addressing rare diseases and improving the utilization rate of plasma [32][33]. - Notable products in development include subcutaneous human immunoglobulin and recombinant coagulation factors, which are expected to contribute to future revenue growth [32][33].